Current and recent projects

• Collaborations with WHO
  • Developing of Target Product Profiles (TPP) to inform product developers, regulatory agencies, procurement agencies and funders on R&D and public health priorities. TPPs are intended to facilitate the most expeditious development of products addressing the greatest and most urgent public health need.
  • Analysis of the global preclinical antibacterial pipeline.
  • Analysis of the global clinical antibacterial and antituberculosis pipeline.
    Update 2018 published in Lancet Infectious Diseases
  • WHO pathogen priority list (PPL) for antibacterial drug R&D.
    Published in Lancet Infectious Diseases
• Contributing to GARDPs (Global Antibiotic Research and Development Partnership) educational programme REVIVE. (Blog, webinar, workshops)
• Member of the independent Scientific Selection Board of the REPAIR Impact Fund to support ambitious programmes addressing antibiotic resistance. Workshops
• Report about the discovery and preclinical antibacterial drug landscape commissioned by the Wellcome Trust in collaboration with the University of Uppsala
• Member of the Advisory Board of CARB-X, a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
• Government funded projects to address the problem of bacterial resistance.
• Member of the member of the GNA NOW Steering Committee, an ongoing project of the IMI2 AMR Accelerator programme.
• Member of the Scientific Advisory Board of the Centre for New Antibacterial Strategies (CANS)
• Work package leader in the EU funded FP7-HEALTH multinational project AIDA (Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics). AIDA was a 5.5 year project (12/2011 – 5/2017) with 6 Million € funding . Three randomized clinical trials supported by an extensive pharmacokinetic, PK/PD, and bacteriological package filled some gaps in our knowledge and provided the basis for a more effective and safe treatment with the studied old antibiotics colistin, nitrofurantoin, fosfomycin trometamol, rifampicin, oral minocycline. AIDA is the first academic, structured, co-ordinated and collaborative project to “re-develop” old antibiotics. Its impact includes revised dosing regimens, regulatory changes, and updated knowledge of 50-70 year old drugs that are increasingly used.
• Work package leader in the European IMI (Innovative Medicines Initiative) project DRIVE-AB which is a collaborative, multinational, public-private consortium with in-kind support from EFPIA partners (European Federation of Pharmaceutical Industries and Associations). DRIVE-AB was a 3 year project (10/2014-12/2017) with 6.3 millin € funding plus in kind contributions from EFPIA.
• Partner in the IMI project COMBACTE-MAGNET (part of the IMI program Combating Antibiotic Resistance: New Drugs for Bad Bugs, ND4BB): Combatting Bacterial Resistance in Europe – Molecules against Gram-Negative Infections. COMBACTE-MAGNET is a 7 year project (1/2015-12/2021) with with 75 million € funding plus in kind contributions from EFPIA.